Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 6/20 | 0.43 |
| ▸ | DRD2 | P14416 | 5/20 | 0.43 |
| ▸ | DRD3 | P35462 | 4/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17844223 | 0.97 | DRD2 (0.41) | DRD4DRD2DRD3RXFP1MAPT | |
| SCHEMBL17844236 | 0.91 | DRD2 (0.44) | DRD4DRD2DRD3MEN1KMT2A | |
| SCHEMBL17844180 | 0.90 | KDM4E (0.37) | RXFP1MAPTMEN1KMT2APOLB | |
| SCHEMBL17844246 | 0.90 | HCRTR1 (0.39) | DRD4DRD2DRD3MEN1KMT2A | |
| SCHEMBL5186747 | 0.89 | PTPN2 (0.37) | DRD4DRD2DRD3POLBGPR84 | |
| SCHEMBL17844247 | 0.89 | HTR1B (0.39) | DRD4DRD2DRD3MAPTMEN1 | |
| SCHEMBL17844230 | 0.89 | DRD2 (0.46) | DRD4DRD2RXFP1MAPTMEN1 | |
| SCHEMBL5184340 | 0.88 | GBA1 (0.35) | MEN1KMT2ATSHRGPR84L3MBTL1 | |
| SCHEMBL17844130 | 0.85 | DRD2 (0.41) | DRD4DRD2DRD3MAPTMEN1 | |
| SCHEMBL17844232 | 0.84 | DRD2 (0.44) | DRD4DRD2DRD3GPR84KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338314-A1 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | THE ROCKEFELLER UNIVERSITY (US) | 2023-10-26 | — | — | US | disclosed |
| US-11648220-B2 | Methods for the treatment of myeloid derived suppressor cells related disorders | THE ROCKEFELLER UNIVERSITY (US) | 2023-05-16 | — | — | US | disclosed |
| US-20190125745-A1 | TREATMENT AND DIAGNOSIS OF CANCER | RGENIX, INC. | 2019-05-02 | — | — | US | disclosed |
| US-20190029984-A1 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | THE ROCKEFELLER UNIVERSITY (US) | 2019-01-31 | — | — | US | disclosed |
| WO-2018222975-A1 | METHODS FOR THE TREATMENT OF CANCER | RGENIX, INC. (US) | 2018-12-06 | — | — | WO | disclosed |
| EP-3402477-A2 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | The Rockefeller University (US) | 2018-11-21 | — | — | EP | disclosed |
| WO-2017123568-A2 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | THE ROCKEFELLER UNIVERSITY (US) | 2017-07-20 | — | — | WO | disclosed |
| WO-2016100619-A2 | TREATMENT AND DIAGNOSIS OF CANCER | RGENIX, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11648220-B2 | Methods for the treatment of myeloid derived suppressor cells related disorders | NR1H3, NR1H2, MCL1 | DRD4 4817/4885DRD2 4788/4885DRD3 4657/4885 |
| US-20230338314-A1 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | NR1H3, NR1H2, MCL1 | DRD4 4817/4885DRD2 4788/4885DRD3 4657/4885 |
| US-20190029984-A1 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | NR1H3, NR1H2, MCL1 | DRD4 4817/4885DRD2 4788/4885DRD3 4657/4885 |
| US-20190125745-A1 | TREATMENT AND DIAGNOSIS OF CANCER | NR1H4, NR1H3, NR1H2 | DRD4 3819/4885DRD2 3454/4885DRD3 3656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.